Abstract BRAF (V600E) mutation is the most frequent genetic alteration in papillary thyroid
carcinomas (PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Abstract Background The BRAF V600E mutation is the most common genetic alteration
found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more …

Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid
carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of …

Context: The oncogenic BRAFV600E mutation has been frequently associated with
aggressive behavior of papillary thyroid carcinomas. However, controversy exists on the …

Context: Evaluation of the degree of neoplastic infiltration beyond the thyroid capsule
remains a unique parameter that can be evaluated by histopathological examination to label …

A high prevalence of the BRAF V600E somatic mutation was recently reported in several
series of papillary thyroid carcinomas (PTC). This mutation appears to be particularly …

B-Raf (BRAF) is the strongest activator in the downstream of MAP kinase signaling. The
somatic point mutation of BRAF gene (V600E) is the most common and specific event in …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …